Price
Financials
Standalone, Rs crore| Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 25.20 | 15.62 | 14.22 | 24.70 | 17.43 | 22.04 | 10.48 | 26.48 | 0.00 | 7.65 | 0.00 | 0.00 |
| Operating costs | 27.47 | 31.54 | 13.18 | 28.19 | 16.41 | 25.71 | 15.31 | 28.98 | 4.72 | 11.67 | 4.31 | 4.68 |
| EBITDA | -2.27 | -15.92 | 1.04 | -3.49 | 1.02 | -3.67 | -4.83 | -2.50 | -4.72 | -4.02 | -4.31 | -4.68 |
| EBITDA margin % | -9.01% | -101.92% | 7.31% | -14.13% | 5.85% | -16.65% | -46.09% | -9.44% | -52.55% | |||
| Depreciation & amortisation | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 |
| Finance costs | 1.30 | 1.22 | 1.16 | 1.23 | 1.54 | 1.68 | 1.58 | 1.74 | 1.67 | 2.06 | 1.72 | 2.09 |
| Non-operating income | 1.20 | 9.08 | 0.25 | 0.22 | 0.12 | 0.59 | 0.14 | 0.32 | 0.10 | 0.49 | 0.10 | 0.16 |
| Pre-tax profit | -2.43 | -8.12 | 0.07 | -4.56 | -0.44 | -4.81 | -6.31 | -3.96 | -6.33 | -5.68 | -5.96 | -6.64 |
| Effective tax rate % | -21.81% | -19.46% | -2,642.86% | 105.26% | -25.00% | -11.02% | -20.76% | -22.22% | -26.07% | -31.69% | -23.15% | -26.05% |
| Profit after tax | -1.89 | -6.53 | 1.93 | -9.36 | -0.33 | -4.28 | -5.00 | -3.08 | -4.68 | -3.88 | -4.59 | -4.92 |
| Earnings per share (Rs) | -0.44 | -1.51 | 0.45 | -2.17 | -0.08 | -0.99 | -1.16 | -0.71 | -1.08 | -0.90 | -1.06 | -1.14 |
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 |
| Operating costs | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 |
| EBITDA | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| EBITDA margin % | 5% | 6% | 2.3% | -3.1% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| Depreciation & amortisation | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finance costs | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Non-operating income | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 |
| Pre-tax profit | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Effective tax rate % | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | |
| Profit after tax | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| Earnings per share (Rs) | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
| Paid out as dividend % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | -13% | 5% | -13% | -90% | ||
| Profit CAGR | % | % | -31% | -42% | ||
| Share price CAGR | -4% | -27% | -22% | -47% | ||
| Average return on equity | -12% | -24% | -23% | -18% |
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current & other assets | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 |
| Total assets | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Share capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves & surplus | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| Total debt | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 |
| Other liabilities & provisions | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 |
| Equity + liabilities | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5 | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Investing cash flow | -0 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 |
| Free cash flow (after capex) | 5 | 32 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Financing cash flow | -3 | -0 | -6 | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 |
| Net change in cash | 2 | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Cash conversion (OCF / EBITDA) % | 89% | 338% | -99% | 229% | 239% | -132% | -32% | 344% | -328% | -56% | 847% | -59% |
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on capital employed % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
| Receivable days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Payable days | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash cycle (days) | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working capital days | -20 | -20 | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
| Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter group % | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% |
| Retail & others % | 40.75% | 40.75% | 40.75% | 40.75% | 40.75% | 40.75% | 40.75% | 40.74% | 40.74% | 40.75% | 40.75% | 40.74% |
| Shareholder count | 38,195 | 36,799 | 36,869 | 36,323 | 35,695 | 35,442 | 36,242 | 35,550 | 34,818 | 34,201 | 34,910 | 35,313 |
Fundamentals
Market value₹ 44.5 Cr.
Last price₹ 10.3
Book value / share₹ 18.2
Return on capital-9.27 %
Return on equity-17.7 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)-90%
Profit CAGR (TTM)-42%
Standalone figures.
Valuation
Market capRs 35 Cr
Enterprise valueRs 97 Cr
Price to book0.40x
Price to sales0.79x
EV / sales2.17x
Price to cash flow3.24x
Earnings yield-51.16%
P/B, 3-year average2.67x
P/B, 5-year average2.06x
Profitability
Operating margin (excl. other income)-41.38%
Operating margin (incl. other income)-35.10%
EBITDA margin-37.84%
Pre-tax margin-55.17%
Net profit margin-40.51%
ROE-17.66%
ROCE-9.27%
ROA-8.56%
ROE, 3-year average-32.22%
ROCE, 3-year average-19.46%
ROA, 3-year average-9.93%
ROE, 5-year average-30.71%
ROCE, 5-year average-18.20%
ROA, 5-year average-8.88%
ROIC (approx.)-8.54%
Tax rate25.33%
Other income / net worth3.19%
Growth
Sales growth (latest year)-43.09%
Sales CAGR, 3 years-12.61%
Sales CAGR, 5 years5.09%
Per share
EPS (TTM)Rs -4.18
EPS (latest year)Rs -3.95
EPS (latest quarter)Rs -1.14
EPS, 3-year averageRs -3.39
EPS, 5-year averageRs -2.78
Book value per shareRs 20.33
Sales per shareRs 10.33
Cash flow per shareRs 2.52
Efficiency
Asset turnover0.24x
Fixed asset turnover0.39x
Inventory turnover30.89x
Inventory days12 days
Debtor days114 days
Debtors turnover3.21x
Leverage
Total debtRs 70 Cr
Cash and bankRs 9 Cr
Net debtRs 61 Cr
Debt to equity0.80x
Interest coverage-2.26x
Owners' fund to total sources47.29%
Debt to assets37.82%
Cash flow
Operating cash flow (latest year)Rs 11 Cr
Investing cash flow (latest year)Rs 0 Cr
Financing cash flow (latest year)Rs -15 Cr
Net change in cash (latest year)Rs -3 Cr
Sales to cash flow4.10x
Statement figures
Net sales (TTM)Rs 45 Cr
Net sales (latest year)Rs 45 Cr
Operating profit excl. other income (latest year)Rs -18 Cr
Operating profit (latest quarter)Rs -5 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs -17 Cr
PBDT (TTM)Rs -24 Cr
Profit before tax (TTM)Rs -25 Cr
Tax (latest year)Rs -6 Cr
Net profit (TTM)Rs -18 Cr
Net profit (latest year)Rs -17 Cr
Net profit (latest quarter)Rs -5 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 8 Cr
Cost of goods sold (latest year)Rs 44 Cr
Total expenditure (latest year)Rs 63 Cr
Total income (latest year)Rs 47 Cr
Share capitalRs 43 Cr
ReservesRs 45 Cr
Shareholders' fundsRs 88 Cr
Total assetsRs 186 Cr
Net blockRs 115 Cr
ReceivablesRs 14 Cr
InventoryRs 1 Cr
Other liabilitiesRs 28 Cr
Shares outstanding (crore)4.32
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.40 is the lowest in 10.1 years (median 1.45).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524663 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -38.3% | -2.8% | -35.5 pts |
| 1 month | -48.7% | -6.8% | -42.0 pts |
| 3 months | -51.2% | -7.6% | -43.6 pts |
| 3 years | -66.2% | +14.2% | -80.4 pts |
| 5 years | -84.7% | +27.9% | -112.6 pts |
Red flags
F-score 3 of 8| explain | Receivables outrunning sales Receivables grew 1128% vs sales -43% in 2023 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Sep 2023Sales ₹0 Cr -100.0% vs Sep 2022.
Net loss ₹5 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd (524663) has a market capitalisation of Rs 44.5 Cr. at the 2026-10-01 close.
What were Bharat Immunological & Biological Corporation Ltd's latest quarterly results?
In the Sep 2023 quarter, Bharat Immunological & Biological Corporation Ltd sales was Rs 0 Cr (-100.0% vs Sep 2022) with a net loss of Rs 5 Cr.